Aged G Protein-Coupled Receptor Kinase 3 (Grk3)-Deficient Mice Exhibit Enhanced Osteoclastogenesis and Develop Bone Lesions Analogous to Human Paget’s Disease of Bone

Paget’s Disease of Bone (PDB) is a metabolic bone disease that is characterized by dysregulated osteoclast function leading to focal abnormalities of bone remodeling. It can lead to pain, fracture, and bone deformity. G protein-coupled receptor kinase 3 (GRK3) is an important negative regulator of G protein-coupled receptor (GPCR) signaling. GRK3 is known to regulate GPCR function in osteoblasts and preosteoblasts, but its regulatory function in osteoclasts is not well defined. Here, we report that Grk3 expression increases during osteoclast differentiation in both human and mouse primary cells and established cell lines. We also show that aged mice deficient in Grk3 develop bone lesions similar to those seen in human PDB and other Paget’s Disease mouse models. We show that a deficiency in Grk3 expression enhances osteoclastogenesis in vitro and proliferation of hematopoietic osteoclast precursors in vivo but does not affect the osteoclast-mediated bone resorption function or cellular senescence pathway. Notably, we also observe decreased Grk3 expression in peripheral blood mononuclear cells of patients with PDB compared with age- and gender-matched healthy controls. Our data suggest that GRK3 has relevance to the regulation of osteoclast differentiation and that it may have relevance to the pathogenesis of PDB and other metabolic bone diseases associated with osteoclast activation.

[1]  Christopher C. Overall,et al.  Senescent cells perturb intestinal stem cell differentiation through Ptk7 induced noncanonical Wnt and YAP signaling , 2023, Nature Communications.

[2]  M. Yamauchi,et al.  Optineurin regulates NRF2-mediated antioxidant response in a mouse model of Paget’s disease of bone , 2023, Science advances.

[3]  Huajun Chen,et al.  De novo analysis of bulk RNA-seq data at spatially resolved single-cell resolution , 2022, bioRxiv.

[4]  C. Rubin,et al.  G protein-coupled receptor kinase 3 modulates mesenchymal stem cell proliferation and differentiation through sphingosine-1-phosphate receptor regulation , 2021, Stem cell research & therapy.

[5]  T. Tarrant,et al.  Paget’s Disease of Bone: Osteoimmunology and Osteoclast Pathology , 2021, Current Allergy and Asthma Reports.

[6]  C. Chung,et al.  Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer. , 2021, Cancer letters.

[7]  Stuart Maudsley,et al.  G Protein-Coupled Receptor Systems and Their Role in Cellular Senescence , 2019, Computational and structural biotechnology journal.

[8]  Anna Teti,et al.  Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions , 2019, Front. Immunol..

[9]  P. Xue,et al.  Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget’s disease , 2019, Cell Death & Differentiation.

[10]  Wanli W. Smith,et al.  Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli , 2019, Journal of cellular and molecular medicine.

[11]  M. Rouleau,et al.  A Novel Reliable and Efficient Procedure for Purification of Mature Osteoclasts Allowing Functional Assays in Mouse Cells , 2018, Front. Immunol..

[12]  S. Ralston,et al.  Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease , 2018, Disease Models & Mechanisms.

[13]  Michael C. Ostrowski,et al.  Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation , 2018, Bone Research.

[14]  A. de Bruin,et al.  Hypoxia negatively affects senescence in osteoclasts and delays osteoclastogenesis , 2018, Journal of cellular physiology.

[15]  I. Kalajzic,et al.  Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen‐induced arthritis , 2016, Clinical and experimental immunology.

[16]  Y. Truong,et al.  G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis , 2016, PloS one.

[17]  Jason A Inzana,et al.  NOTCH signaling in skeletal progenitors is critical for fracture repair. , 2016, The Journal of clinical investigation.

[18]  P. Cohen,et al.  Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget’s Disease , 2015, Cell reports.

[19]  Shi Wei,et al.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis* , 2015, The Journal of Biological Chemistry.

[20]  M. Murad,et al.  Bone turnover markers in Paget’s disease of the bone: A Systematic review and meta-analysis , 2015, Osteoporosis International.

[21]  T. Yuen,et al.  Bisphosphonates inactivate human EGFRs to exert antitumor actions , 2014, Proceedings of the National Academy of Sciences.

[22]  I. Reid,et al.  Paget's disease of bone: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  D. Galson,et al.  Pathobiology of Paget's Disease of Bone , 2014, Journal of bone metabolism.

[24]  T. Tarrant,et al.  Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease , 2014, Current Allergy and Asthma Reports.

[25]  D. Siderovski,et al.  G protein‐coupled receptor kinase‐3‐deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses , 2013, Journal of leukocyte biology.

[26]  J. Walsh,et al.  New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone. , 2013, Endocrine reviews.

[27]  S. Ralston,et al.  A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. , 2011, Human molecular genetics.

[28]  Mitch Dowsett,et al.  Current and emerging biomarkers in breast cancer: prognosis and prediction. , 2010, Endocrine-related cancer.

[29]  J. Kieft,et al.  Elevated histone expression promotes life span extension. , 2010, Molecular cell.

[30]  Stuart L Schreiber,et al.  Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres , 2010, Nature Structural &Molecular Biology.

[31]  William D Fraser,et al.  Genome wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone , 2010, Nature Genetics.

[32]  I. Reid,et al.  Pathogenesis and management of Paget's disease of bone , 2008, The Lancet.

[33]  A. Su,et al.  Expression analysis of G Protein-Coupled Receptors in mouse macrophages , 2008, Immunome research.

[34]  H. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[35]  S. Ralston,et al.  Identification of Sex‐Specific Associations Between Polymorphisms of the Osteoprotegerin Gene, TNFRSF11B, and Paget's Disease of Bone , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  D. Dempster,et al.  Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. , 2007, The Journal of clinical investigation.

[37]  A. Rapado,et al.  Clinical usefulness of serum tartrate-resistant acid phosphatase in paget's disease of bone: Correlation with other biochemical markers of bone demodelling , 2007, Calcified Tissue International.

[38]  H. Aguila,et al.  Identification of Multiple Osteoclast Precursor Populations in Murine Bone Marrow , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  L. Hocking,et al.  SQSTM1 and Paget’s Disease of Bone , 2004, Calcified Tissue International.

[40]  L. Hocking,et al.  Susceptibility to Paget's Disease of Bone Is Influenced by a Common Polymorphic Variant of Osteoprotegerin , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  R. Spurney Regulated Expression of G Protein-Coupled Receptor Kinases (GRK’s) and β-Arrestins in Osteoblasts , 2003, Calcified Tissue International.

[42]  Jacques P. Brown,et al.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. , 2002, American journal of human genetics.

[43]  S. C. Garner,et al.  Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. , 2002, The Journal of clinical investigation.

[44]  A. Scillitani,et al.  Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone , 2002, Osteoporosis International.

[45]  R. Spurney,et al.  Domains of the parathyroid hormone (PTH) receptor required for regulation by G protein-coupled receptor kinases (GRKs). , 2001, Biochemical pharmacology.

[46]  Robert J. Lefkowitz,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[47]  Marc G. Caron,et al.  G Protein-coupled Receptor Kinase 3 (GRK3) Gene Disruption Leads to Loss of Odorant Receptor Desensitization* , 1997, The Journal of Biological Chemistry.

[48]  R. Deulofeu,et al.  Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.